DataSheet_1：肉瘤样肝细胞癌患者基因检测与预后数据表

数据集获取（Figshare）

• 源站标题：DataSheet_1_Genetic testing and prognosis of sarcomatoid hepatocellular carcinoma patients.zip
• DOI：10.3389/fonc.2022.1086908.s001
• 发布日期：2023-01-18
• 文件数：1 个
• 文件总体积：195.89 KB
• 源站页面：https://frontiersin.figshare.com/articles/dataset/DataSheet_1_Genetic_testing_and_prognosis_of_sarcomatoid_hepatocellular_carcinoma_patients_zip/21916485

命令行下载

curl -L -o "DataSheet_1_Genetic testing and prognosis of sarcomatoid hepatocellular carcinoma patients.zip" "https://ndownloader.figshare.com/files/38878557"

文件清单

• DataSheet_1_Genetic testing and prognosis of sarcomatoid hepatocellular carcinoma patients.zip（195.89 KB）

文件总体积 195.89 KB（源站 API 实测）。

数据说明

BackgroundSarcomatoid hepatocellular carcinoma (SHC) is a rare epithelial malignancy with high invasiveness and poor prognosis. However, the molecular characteristics and main driver genes for SHC have not been determined. The aim of this study is to explore the potentially actionable mutations of driver genes, which may provide more therapeutic options for SHC.
MethodsIn this study, DNA extraction and library preparation were performed using tumor tissues from 28 SHC patients. Then we used Miseq platform (Illumina) to sequence the target-enriched library, and we aligned and processed the sequencing data. The gene groups were tested for SNVs/Indels/CNVs. Tumor mutation burden (TMB) was assessed by the 425-cancer-relevant gene panel. Multivariate analysis of COX’s model was used for survival analysis (OS) of patients’ clinical characteristics.
ResultThe median overall survival (OS) of the patients was only 4.4 months. TP53, TERT, and KRAS were the top three frequently mutated genes, with frequencies of 89.3%, 64.3%, and 21.4%, respectively. A considerable number of patients carried mutations in genes involved in the TP53 pathway (96%) and DNA Damage Repair (DDR) pathway (21%). Multiple potentially actionable mutations, such as NTRK1 fusions and BRCA1/2 mutations, were identified in SHCs.
ConclusionsThis study shows a landscape of gene mutations in SHC. SHC has high mutation rates in TP53 pathway and DDR pathway. The potentially actionable mutations of driver genes may provide more therapeutic options for SHC. Survival analysis found that age, smoking, drinking, and tumor diameter may be independent prognostic predictors of SHC.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.3389/fonc.2022.1086908.s001（source: https://frontiersin.figshare.com/articles/dataset/DataSheet_1_Genetic_testing_and_prognosis_of_sarcomatoid_hepatocellular_carcinoma_patients_zip/21916485）。